Saturday 17 October 2026
Export LMRI’s income statement to Excel — free account
Lumexa Imaging Holdings, Inc.
LMRI Healthcare Medical Devices
Lumexa Imaging Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.82% from fiscal 2024. In the quarter to June 2026, revenue grew 7.82%, EPS grew 127.1% and free cash flow grew 257.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.64
0.14
−1.30%
Follow LMRI
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+3 more quarters Free account |
P/S ratio |
0.60 | 0.47 | 0.00 | 0.00 | |
P/FCF ratio |
72.51 | 0.00 | 0.00 | 128.20 | |
P/Operating CF |
33.01 | 281.53 | 76.91 | 621.15 | |
P/B ratio |
1.76 | 1.38 | 2.24 | 7.97 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 7.97 | |
EV/Sales |
1.05 | 0.93 | 0.00 | 0.00 | |
EV/EBITDA |
1.66 | 1.44 | 0.00 | 0.00 | |
EV/Operating CF |
34.41 | 202.43 | 46.17 | 37.36 | |
EV/FCF |
126.46 | (71.81) | (293.46) | 246.79 | |
Quick Ratio |
1.36 | 1.30 | 1.17 | — | |
Current Ratio |
1.44 | 1.41 | 1.27 | — | |
Net Debt/EBITDA |
20.96 | 23.93 | 0.79 | 0.00 | |
Debt/Assets |
48.39% | 49.28% | 49.04% | 0.00% | |
Debt/Equity |
1.42 | 1.45 | 1.48 | 0.00 | |
Asset Turnover |
1.98 | 1.03 | 0.00 | — | |
Operating CF/Net income |
11.95 | 1.71 | (0.36) | (0.29) | |
Capex/Depreciation |
(0.63) | (0.36) | (0.34) | (0.29) | |
Interest Coverage |
1.42 | 1.19 | — | 0.92 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
9.24% | 8.05% | 0.00% | 7.43% | |
Intangible Assets out of Total Assets |
0.47 | 0.48 | 0.48 | 0.00 | |
Share Based Compensation of Revenue |
4.82% | 4.86% | 0.00% | 3.32% | |
Graham Net Nets |
(0.87) | (1.14) | (0.72) | (1.04) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.33%) | (9.94%) | (9.94%) | (9.94%) | |
Free Cash Flow Yield |
1.38% | (2.77%) | (0.55%) | 0.78% | |
Revenue per Share |
2.75 | 2.63 | 14.41 | 3.62 | |
Operating CF per Share |
0.34 | 0.03 | 0.24 | 0.03 | |
Capex per Share |
(0.10) | (0.05) | (0.29) | (0.06) | |
Free Cash Flow per Share |
0.24 | (0.02) | (0.05) | (0.03) | |
Cash per Share |
0.73 | 0.53 | 0.83 | 0.00 | |
Shareholders Equity per Share |
6.41 | 6.25 | 8.26 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.41 | 6.25 | 8.26 | 0.00 | |
Free Cash Flow |
23.13 | (2.34) | (3.76) | (2.10) | |
Working Capital |
78.06 | 63.96 | 48.07 | — | |
Capital Expenditures |
(9.67) | (5.27) | (20.83) | (4.17) | |
Net Current Asset Value |
(937.29) | (941.84) | (951.17) | 0.00 | |
EV/EBIT |
1.73 | 1.50 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
0.99 | 0.75 | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
904.39 | 1,716.96 | 882.28 | — |
Columns are period end dates